Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (121-130 of 346) with videos related to

Pageof 35
Sort By:
Leukemia & Lymphoma|June 1, 2026
Latency between detectable low-level MRD by next-generation sequencing and overt relapse in ALL: implications for the optimal frequency of MRD monitoringTrevor Jamison, Elias Jabbour, Omer Karrar, et al.
Blood|May 29, 2016
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Koji Sasaki, et al.
Leukemia & Lymphoma|February 2, 2026
Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemiaJacob E Herstein, Kayleigh R Marx, Fadi G Haddad, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 22, 2025
Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class RearrangementsJulie Braish, Hagop Kantarjian, Nicholas J Short, et al.
Frontiers in Oncology|February 2, 2026
Case Report: FIA plus venetoclax in a patient on hemodialysisJacob E Herstein, Kayleigh R Marx, J Michael Savoy, et al.
Archives of Pathology & Laboratory Medicine|June 16, 2025
Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient CohortSa A Wang, Shaoying Li, Wei Wang, et al.
Leukemia & Lymphoma|August 19, 2025
Mortality and relapse dynamics in AML after three years of complete remissionSamuel Urrutia, Wei-Ying Jen, Koji Sasaki, et al.
American Journal of Hematology|May 28, 2022
Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemiaShilpa Paul, Hagop Kantarjian, Koji Sasaki, et al.
American Journal of Hematology|March 7, 2019
NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemiaHussein A Abbas, Farhad Ravandi, Sanam Loghavi, et al.
American Journal of Hematology|August 28, 2024
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemiaWei-Ying Jen, Elias Jabbour, Nicholas J Short, et al.
Pageof 35

Showing results (121-130 of 346) with videos related to

Sort By:
Pageof 35
Leukemia & Lymphoma|June 1, 2026
Latency between detectable low-level MRD by next-generation sequencing and overt relapse in ALL: implications for the optimal frequency of MRD monitoringTrevor Jamison, Elias Jabbour, Omer Karrar, et al.
Blood|May 29, 2016
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaNicholas J Short, Elias Jabbour, Koji Sasaki, et al.
Leukemia & Lymphoma|February 2, 2026
Case series: rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for myelodysplastic syndrome and relapsed/refractory acute myeloid leukemiaJacob E Herstein, Kayleigh R Marx, Fadi G Haddad, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 22, 2025
Tyrosine Kinase Inhibitors During Frontline Therapy in Adults With Acute Lymphoblastic Leukemia With ABL-class RearrangementsJulie Braish, Hagop Kantarjian, Nicholas J Short, et al.
Frontiers in Oncology|February 2, 2026
Case Report: FIA plus venetoclax in a patient on hemodialysisJacob E Herstein, Kayleigh R Marx, J Michael Savoy, et al.
Archives of Pathology & Laboratory Medicine|June 16, 2025
Technical and Clinical Validity of Assessing Measurable Residual Disease by Multicolor Flow Cytometry in an Unselected Acute Myeloid Leukemia Patient CohortSa A Wang, Shaoying Li, Wei Wang, et al.
Leukemia & Lymphoma|August 19, 2025
Mortality and relapse dynamics in AML after three years of complete remissionSamuel Urrutia, Wei-Ying Jen, Koji Sasaki, et al.
American Journal of Hematology|May 28, 2022
Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemiaShilpa Paul, Hagop Kantarjian, Koji Sasaki, et al.
American Journal of Hematology|March 7, 2019
NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemiaHussein A Abbas, Farhad Ravandi, Sanam Loghavi, et al.
American Journal of Hematology|August 28, 2024
A phase 2 trial of mini-hyper-CVD, blinatumomab, and ponatinib in Philadelphia positive acute lymphoblastic leukemiaWei-Ying Jen, Elias Jabbour, Nicholas J Short, et al.
Pageof 35